Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $1.9 million.

  • Prime Medicine's Depreciation & Amortization (CF) rose 2073.17% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 2658.18%. This contributed to the annual value of $6.1 million for FY2024, which is 3170.0% up from last year.
  • Per Prime Medicine's latest filing, its Depreciation & Amortization (CF) stood at $1.9 million for Q3 2025, which was up 2073.17% from $1.9 million recorded in Q2 2025.
  • Prime Medicine's Depreciation & Amortization (CF)'s 5-year high stood at $1.9 million during Q3 2025, with a 5-year trough of $200000.0 in Q3 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $1.2 million (2023), whereas its average is $1.1 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 25904.44% in 2023, then soared by 2073.17% in 2025.
  • Prime Medicine's Depreciation & Amortization (CF) (Quarter) stood at $261000.0 in 2021, then skyrocketed by 233.33% to $870000.0 in 2022, then surged by 43.33% to $1.2 million in 2023, then skyrocketed by 37.69% to $1.7 million in 2024, then grew by 9.55% to $1.9 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $1.9 million for Q3 2025, versus $1.9 million for Q2 2025 and $1.7 million for Q1 2025.